Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II

Mise à jour : Il y a 5 ans
Référence : NCT00091715

Femme et Homme

Extrait

The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.


Critère d'inclusion

  • pulmonary hypertension


Liens